Advertisement

Clinical PET pp 262-282 | Cite as

Thoracic Cancer

  • E. Edmund Kim
  • Franklin C. L. Wong
Chapter
  • 251 Downloads

Abstract

Lung cancer is the most frequently diagnosed cancer in the world, and the prevalence of lung cancer is increasing globally.1 It is the leading cause of death from cancer, and the death occurs at a higher frequency in men than in women in most parts of the world.2 There were 169,400 estimated new cases in 2002. Lung cancer claims approximately 150,900 lives each year in the United States, and 20,000 more women died of lung cancer than breast cancer in 2002.3 The survival rate is poor, largely because lung cancer is usually diagnosed at an advanced stage. The overall 5-year survival of patients with lung cancer is approximately 14% and has remained unchanged over several decades despite aggressive treatment protocols.3 Therefore, new diagnostic and treatment strategies are needed if an impact is to be made on the survival of patients with lung cancer. A cure may be achieved by surgery, which is feasible only in patients who present at an early stage. However, even in this early stage, approximately 75% patients will die of recurrent disease.1,4 Lung cancer is rare before the age of 40, after which age-specific rates rise sharply. The ages with the greatest incidence are between 65 and 79.1

Keywords

Lung Cancer Standard Uptake Value Small Cell Carcinoma Axial Body Bronchogenic Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Smith RA, Glynn TJ. Epidemiology of lung cancer. Radiol Clin North Am 2000; 38: 453–470.PubMedCrossRefGoogle Scholar
  2. 2.
    Magrath I, Litvak J. Cancer in developing countries: opportunity and challenge. J Natl Cancer Inst 1993; 85: 862–873.PubMedCrossRefGoogle Scholar
  3. 3.
    Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52: 23–47.PubMedCrossRefGoogle Scholar
  4. 4.
    Bepler G. Lung cancer epidemiology and genetics. J Thorac Imaging 1999; 14: 228–234.PubMedCrossRefGoogle Scholar
  5. 5.
    Quint LE, Francis IR. Radiologic staging of lung cancer. J Thorac Imaging 1999; 14: 235–246.PubMedCrossRefGoogle Scholar
  6. 6.
    Mack MJ, Hazelrigg JR, Landreneau RJ, Acuft TE. Thoracoscopy for the diagnosis of the indeterminate solitary pulmonary nodule. Ann Thorac Surg 1993; 56: 825–832.PubMedCrossRefGoogle Scholar
  7. 7.
    Smith TAD. FDG uptake, tumor characteristics, and response to therapy: a review. Nucl Med Commun 1998; 19: 97–105.PubMedCrossRefGoogle Scholar
  8. 8.
    Ginsberg RS, Vokes EE, Rosenzweig K. Non-small cell cancer of the lung. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology, 6th ed. Philadelphia, Lippincott-Raven, 2002:925982.Google Scholar
  9. 9.
    Sone S, Sakai F, Takashima S, et al. Factors affecting the radiologic appearance of peripheral bronchogenic carcinomas. J Thorac Imaging 1997; 12: 159–172.PubMedCrossRefGoogle Scholar
  10. 10.
    Mountain C, Libshitz HI, Hermes KE. Lung Cancer: A Handbook for Staging and Imaging. Houston: University of Texas M.D. Anderson Cancer Center, 1992.Google Scholar
  11. 11.
    Yankelevitz DF, Henschke CI. Small solitary pulmonary nodules. Radiol Clin North Am 2000; 38: 471–478.PubMedCrossRefGoogle Scholar
  12. 12.
    Romney BM, Austin JH. Plain film evaluation of carcinoma of the lung. Semin Roetgenol 1990; 25: 45–63.CrossRefGoogle Scholar
  13. 13.
    Bouchard EW, Falken S, Molina PL. Lung cancer: a radiologic overview. Appl Radiol 2002; 7–19.Google Scholar
  14. 14.
    Swensen SJ, Morin RL, Schueller B, et al. Solitary pulmonary nodule: CT evaluation of enhancement with iodinated contrast material-a preliminary report. Radiology 1992; 182: 343–347.PubMedGoogle Scholar
  15. 15.
    Schuster MR, Scanlan KA. “CT angiogram sign” establishing the differential diagnosis. Radiology 1991; 178: 90–95.Google Scholar
  16. 16.
    Park BJ, Louie D, Altorki N. Staging and the surgical management of lung cancer. Radiol Clin North Am 2000; 38: 545–558.PubMedCrossRefGoogle Scholar
  17. 17.
    Obuchowski NA, Graham RI, Baker ME, Powell KA. Ten criteria for effective screening: their application to multislice CT screening for pulmonary and colorectal cancers. AIR 2001; 176: 1357–1362.Google Scholar
  18. 18.
    Henschke CI, Yankelevitz DF. Screening for lung cancer. J Thorac Imaging 2000; 15: 21–27.PubMedCrossRefGoogle Scholar
  19. 19.
    Hatabu H, Syock KW, Sher S, et al. Magnetic resonance imaging of the thorax. Radiol Clin North Am 2000; 38: 593–616.PubMedCrossRefGoogle Scholar
  20. 20.
    Flier JS, Mueckler MM, Usher P, et al. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987; 235: 1492–1495.PubMedCrossRefGoogle Scholar
  21. 21.
    Coleman RE. PET in lung cancer. J Nucl Med 1999; 40: 814–820.PubMedGoogle Scholar
  22. 22.
    Lowe VJ, DeLong DM, Hoffman JM, Coleman RE. Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy. J Nucl Med 1995; 36: 883–887.PubMedGoogle Scholar
  23. 23.
    Gould MK, Maclean CC, Kuschner WG, et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta analysis. JAMA 2001; 285: 914–924.PubMedCrossRefGoogle Scholar
  24. 24.
    Gambhir SS, Czernim J, Schwimmer J, et al. A tabulated summary of the FDG-PET literature. N Nucl Med 2001; 42 (suppl): 1S - 92S.Google Scholar
  25. 25.
    Graeber GM, Gupta NC, Murray GF. Positron emission tomographic imaging with fluorodeoxyglucose is efficacious in evaluating malignant pulmonary disease. J Thorac Cardiovasc Surg 1999; 117: 719–727.PubMedCrossRefGoogle Scholar
  26. 26.
    Pieterman RM,VanPutten JWG, Meuzelaar JJ, et al. Preoperative staging of non-small cell lung cancer with positron emission tomography. N Engl J Med 2000; 343: 254–261.Google Scholar
  27. 27.
    Hicks RJ, Kalff V, MacManus MP, et al. 18F-FDG-PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med 2001; 42: 1596–1604.PubMedGoogle Scholar
  28. 28.
    Kernstine KH, McLaughlin KA, Menda Y, et al. Can FDG-PET reduce the need for mediastinoscopy in potentially resectable nonsmall cell lung cancer? Ann Thorac Surg 2002; 73: 394–402.PubMedCrossRefGoogle Scholar
  29. 29.
    Patz EF Jr, Lowe VJ, Hoffman JM, et al. Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-181–2-deoxy-D-glucose. Radiology 1994; 191: 379–382.PubMedGoogle Scholar
  30. 30.
    Inoue T, Kim EE, Komaki R, et al. Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 1995; 36: 788–793.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • E. Edmund Kim
  • Franklin C. L. Wong

There are no affiliations available

Personalised recommendations